| Textiles, Apparel & Luxury Goods Industry | Consumer Discretionary Sector | Sascha Knoche CEO | MSE Exchange | INE012Q01021 ISIN |
| Germany Country | 39 Employees | - Last Dividend | 2 Apr 2026 Last Split | - IPO Date |
Arzneiwerk AG VIDA is a pioneering pharmaceutical company situated in Berlin, Germany, renowned for its dedicated efforts in supplying medications for newly developed or rare diseases across Europe. Initially known as TELES Aktiengesellschaft, the company underwent a significant transformation, adopting its current name in July 2024. This strategic rebranding marked a pivotal shift towards focusing exclusively on the unique challenges and requirements associated with rare and newly discovered medical conditions. Arzneiwerk AG VIDA’s mission is underpinned by a strong commitment to innovating within the pharmaceutical landscape, ensuring that those in need have access to critical, life-saving medicines.
Arzneiwerk AG VIDA’s product and service portfolio is meticulously designed to address the complex needs of patients suffering from rare and newly identified diseases. Each offering is characterized by a focus on innovation, accessibility, and effectiveness.
This service focuses on the sourcing and distribution of drugs for rare diseases, a critical area often overlooked by larger pharmaceutical companies. Arzneiwerk AG VIDA collaborates with research institutions and healthcare providers to ensure these vital medications are accessible to those in need.
Understanding the importance of innovation in healthcare, Arzneiwerk AG VIDA also specializes in the distribution of recently developed drugs. This includes medicines that have just passed clinical trials and received approval for public use, offering hope and new solutions for patients with complex health issues.